At a glance
ClinicalIndex Comparison RecordN/ACompleted· 595 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-Marketing Surveillance of Safety and Efficacy of Kaletra® Tablet in Korean Patients Under the "New Drug Re-Examination"
In Brief
An observational study for HIV-1 Infection. Completed, enrolled 595 participants.
Detailed Summary
This single-arm, multi-center, Post-Marketing Surveillance study of Kaletra (lopinavir/ritonavir) was conducted in accordance with the approved Korean product labeling in participants 2 years of age and older with human immunodeficiency virus type 1 (HIV-1) infection.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infection
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedMar 2010
Primary CompletionOct 2014
TodayJul 2026
First PostedMar 9, 2010
Enrollment StartOct 1, 2009
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 16.3 years ago